Scott B Halstead

Summary

Country: USA

Publications

  1. ncbi More dengue, more questions
    Scott B Halstead
    Pediatric Dengue Vaccine Initiative, Rockville, Maryland 20852, USA
    Emerg Infect Dis 11:740-1. 2005
  2. ncbi Dengue virus-mosquito interactions
    Scott B Halstead
    Pediatric Dengue Vaccine Initiative, Bethesda, MD 20852, USA
    Annu Rev Entomol 53:273-91. 2008
  3. ncbi Measuring dengue enhancing antibodies: caveats
    Scott B Halstead
    J Infect Dis 193:601. 2006
  4. ncbi Interview with Scott B. Halstead, M.D
    Scott B Halstead
    Vector Borne Zoonotic Dis 7:99-105. 2007
  5. ncbi The burden of dengue infection
    Scott B Halstead
    Pediatric Dengue Vaccine Initiative, Rockville, MD 20852, USA
    Lancet 369:1410-1. 2007
  6. ncbi Controversies in dengue pathogenesis
    Scott B Halstead
    Dengue Vaccine Initiative, International Vaccine Institute, Seoul, Korea
    Paediatr Int Child Health 32:5-9. 2012
  7. ncbi Antibodies determine virulence in dengue
    Scott B Halstead
    Supportive Research and Development Program, Pediatric Dengue Vaccine Initiative, Bethesda, Maryland 20852, USA
    Ann N Y Acad Sci 1171:E48-56. 2009
  8. ncbi Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria
    Scott B Halstead
    Pediatric Dengue Vaccine Initiative, 5824 Edson Lane, Rockville, MD 20852, USA
    Vaccine 23:849-56. 2005
  9. ncbi Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii
    Scott B Halstead
    Department of Tropical Medicine and Medical Microbiology, John A Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA
    Am J Trop Med Hyg 69:5-11. 2003
  10. ncbi Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes
    Scott B Halstead
    International Vaccine Institute, Seoul, Korea
    Lancet Infect Dis 10:712-22. 2010

Collaborators

Detail Information

Publications38

  1. ncbi More dengue, more questions
    Scott B Halstead
    Pediatric Dengue Vaccine Initiative, Rockville, Maryland 20852, USA
    Emerg Infect Dis 11:740-1. 2005
  2. ncbi Dengue virus-mosquito interactions
    Scott B Halstead
    Pediatric Dengue Vaccine Initiative, Bethesda, MD 20852, USA
    Annu Rev Entomol 53:273-91. 2008
    ..Also described is the crucial role of monotypic and heterotypic herd immunity in shaping dengue epidemic behavior...
  3. ncbi Measuring dengue enhancing antibodies: caveats
    Scott B Halstead
    J Infect Dis 193:601. 2006
  4. ncbi Interview with Scott B. Halstead, M.D
    Scott B Halstead
    Vector Borne Zoonotic Dis 7:99-105. 2007
  5. ncbi The burden of dengue infection
    Scott B Halstead
    Pediatric Dengue Vaccine Initiative, Rockville, MD 20852, USA
    Lancet 369:1410-1. 2007
  6. ncbi Controversies in dengue pathogenesis
    Scott B Halstead
    Dengue Vaccine Initiative, International Vaccine Institute, Seoul, Korea
    Paediatr Int Child Health 32:5-9. 2012
    ....
  7. ncbi Antibodies determine virulence in dengue
    Scott B Halstead
    Supportive Research and Development Program, Pediatric Dengue Vaccine Initiative, Bethesda, Maryland 20852, USA
    Ann N Y Acad Sci 1171:E48-56. 2009
    ....
  8. ncbi Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria
    Scott B Halstead
    Pediatric Dengue Vaccine Initiative, 5824 Edson Lane, Rockville, MD 20852, USA
    Vaccine 23:849-56. 2005
    ..Achievement of this aim will require a better understanding of the basic mechanisms by which dengue viruses recognize, attach, enter and infect relevant human cells and how antibodies protect against dengue infections...
  9. ncbi Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii
    Scott B Halstead
    Department of Tropical Medicine and Medical Microbiology, John A Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA
    Am J Trop Med Hyg 69:5-11. 2003
    ..Candidate human vaccines have been prepared from five of the studied strains: DEN-1 (16007) at PDK 13, DEN-2 (16681 and S-16803) at PDK 50 or above, and DEN-4 (1036 and 341750) at PDK 48 and 20, respectively...
  10. ncbi Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes
    Scott B Halstead
    International Vaccine Institute, Seoul, Korea
    Lancet Infect Dis 10:712-22. 2010
    ..We review insights into intracellular mechanisms and implications of enhanced pathogenesis after ligation of macrophage Fcγ receptors by infectious immune complexes...
  11. ncbi Dengue
    Scott B Halstead
    Supportive Research and Development, Pediatric Dengue Vaccine Initiative, Internal Vaccine Institute, Seoul, South Korea
    Lancet 370:1644-52. 2007
    ..Here, I review and discuss data on clinical diagnosis and pathophysiology of vascular permeability and coagulopathy, parenteral treatment of DHF/DSS, and new laboratory tests...
  12. ncbi Dengue
    Scott B Halstead
    Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20852, USA
    Curr Opin Infect Dis 15:471-6. 2002
    ..Because efforts to control dengue are flagging, this review focuses on the mechanisms underlying severe disease and on treatment options, good and bad...
  13. ncbi Dengue hemorrhagic fever in infants: research opportunities ignored
    Scott B Halstead
    Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Emerg Infect Dis 8:1474-9. 2002
    ..Research challenges presented by infant DHF/DSS are discussed...
  14. ncbi The future of dengue vaccines
    Scott B Halstead
    Department of Preventive Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Lancet 360:1243-5. 2002
  15. ncbi New vaccines for Japanese encephalitis
    Scott B Halstead
    Research Program, Pediatric Dengue Vaccine Initiative, 5824 Edson Lane, Rockville, MD, 20852, USA
    Curr Infect Dis Rep 12:174-80. 2010
    ..Safe and effective JE vaccines are now available to the entire at-risk population and should greatly diminish the burden of disease...
  16. ncbi New Japanese encephalitis vaccines: alternatives to production in mouse brain
    Scott B Halstead
    Research Program, Pediatric Dengue Vaccine Initiative, 5824 Edson Lane, Rockville, MD 20852, USA
    Expert Rev Vaccines 10:355-64. 2011
    ..A broad portfolio of safe and effective Japanese encephalitis vaccines has become available to meet the needs of at-risk populations; when appropriately delivered, these new vaccines should greatly diminish the burden of disease...
  17. ncbi Japanese encephalitis: new options for active immunization
    Scott B Halstead
    Research Program, Pediatric Dengue Vaccine Initiative, Rockville, Maryland 20852, USA
    Clin Infect Dis 50:1155-64. 2010
    ..JE is a vaccine-preventable disease with numerous options now available for active immunization. Aggressive and responsible vaccination programs should greatly diminish the burden of disease...
  18. ncbi How innate immune mechanisms contribute to antibody-enhanced viral infections
    Sukathida Ubol
    Microbiology Department, Faculty of Science, Mahidol University, 272 Rama 6 Road, Bangkok 10400, Thailand
    Clin Vaccine Immunol 17:1829-35. 2010
    ..Safe and effective vaccines against RSV/measles virus and dengue virus may benefit from a better understanding of how innate immune responses can promote production of protective antibodies...
  19. ncbi The wages of original antigenic sin
    David M Morens
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Emerg Infect Dis 16:1023-4. 2010
  20. ncbi Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study
    Heechoul Ohrr
    Department of Preventive Medicine, Yonsei University College of Medicine, Seoul 120 752, Korea
    Lancet 366:1375-8. 2005
    ..Cases of natural infection occurred almost immediately. Our aim was to assess the long-term protective effect of this vaccination...
  21. ncbi Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards
    Mark E Beatty
    Pediatric Dengue Vaccine Initiative, International Vaccine Institute, Seoul, Republic of Korea
    PLoS Negl Trop Dis 4:e890. 2010
    ..Dengue fever is a virus infection that is spread by the Aedes aegypti mosquito and can cause severe disease especially in children. Dengue fever is a major problem in tropical and sub-tropical regions of the world...
  22. ncbi Japanese encephalitis
    Scott B Halstead
    Department of Preventive Medicine and Biometrics, Uniformed University of the Health Sciences, Bethesda, Maryland 20814, USA
    Adv Virus Res 61:103-38. 2003
  23. ncbi Neutralization and antibody-dependent enhancement of dengue viruses
    Scott B Halstead
    Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    Adv Virus Res 60:421-67. 2003
  24. ncbi Dengue in the Americas and Southeast Asia: do they differ?
    Scott B Halstead
    Pediatric Dengue Vaccine Initiative Research, 5824 Edson Lane, Rockville, Maryland 20852, United States of America
    Rev Panam Salud Publica 20:407-15. 2006
    ..Understanding the nature and distribution of these genes holds promise for containing severe dengue. Future research on dengue infections should emphasize population-based designs...
  25. ncbi Neutralizing antibodies after infection with dengue 1 virus
    Maria G Guzman
    Pedro Kouri Tropical Medicine Institute, Havana, Cuba
    Emerg Infect Dis 13:282-6. 2007
    ..This finding may be related to the time-dependent changes in severity of disease found with secondary dengue infection...
  26. ncbi Natural history of dengue virus (DENV)-1 and DENV-4 infections: reanalysis of classic studies
    Hiroshi Nishiura
    Department of Medical Biometry, University of Tubingen, Tubingen, D 72070, Germany
    J Infect Dis 195:1007-13. 2007
    ..The natural history of wild-type dengue virus (DENV) infections of humans, including incubation and infectious periods, requires further study...
  27. ncbi Effect of age on outcome of secondary dengue 2 infections
    Maria G Guzman
    Department of Virology, PAHO WHO Collaborating Center for Viral Diseases, Tropical Medicine Institute of Havana, Cuba
    Int J Infect Dis 6:118-24. 2002
    ..Involved were individuals, 3-40 year old, whose only lifetime dengue exposure was to DEN-1 in 1977 and DEN-2 in 1981. In this report we calculate age-specific DHF/DSS hospitalization and death rates based on secondary DEN 2 infections...
  28. ncbi Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever
    Tadeusz J Kochel
    Department of Virology, Naval Medical Research Centre Detachment, Lima, Peru
    Lancet 360:310-2. 2002
    ....
  29. ncbi Vaccines aplenty
    Scott B Halstead
    Curr Opin Infect Dis 15:461-3. 2002
  30. ncbi Cost-effectiveness of a pediatric dengue vaccine
    Donald S Shepard
    Schneider Institute for Health Policy, Heller School, Room G19, Mail Stop 035, Brandeis University, Waltham, MA 02454 9110, USA
    Vaccine 22:1275-80. 2004
    ..Eventually, vaccination may be able to replace environmental control as a strategy for dengue prevention and be cost saving...
  31. ncbi Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks
    Maria G Guzman
    Institute of Tropical Medicine Pedro Kouri, Department of Virology, Tropical Medicine Institute, Autopista Novia del Mediodía Km 6, P O Box 601, Marianao 13, Havana, Cuba
    Rev Panam Salud Publica 11:223-7. 2002
    ..To understand the possible effect that length of time has on disease severity with sequential dengue infections...
  32. ncbi Volume replacement in infants with dengue hemorrhagic fever/dengue shock syndrome
    Thanh Hung Nguyen
    Department of Dengue Hemorrhagic Fever, Children s Hospital No 1, Ho Chi Minh City, Vietnam
    Am J Trop Med Hyg 74:684-91. 2006
    ..To improve case fatality rates, special efforts need to be directed to infants with DHF/DSS accompanied by severe complications...
  33. ncbi Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002
    Mayling Alvarez
    Department of Virology, Pan American Health Organization/World Health Organization Collaborating Center for the Study of Dengue and Its Vector, , Havana, Cuba
    Am J Trop Med Hyg 75:1113-7. 2006
    ..However definitive categorization of a tertiary infection was not possible because of broadly reactive antibodies, which could have been raised by infections in the sequence DENV-1 then DENV-3...
  34. ncbi Association between sex, nutritional status, severity of dengue hemorrhagic fever, and immune status in infants with dengue hemorrhagic fever
    Thanh Hung Nguyen
    Department of Dengue Hemorrhagic Fever, Children s Hospital No 1, Ho Chi Minh City, Vietnam
    Am J Trop Med Hyg 72:370-4. 2005
    ....
  35. ncbi Dengue hemorrhagic fever: two infections and antibody dependent enhancement, a brief history and personal memoir
    Scott B Halstead
    Department of Molecular Microbiology and Immunology, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
    Rev Cubana Med Trop 54:171-9. 2002
  36. ncbi Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles
    Thanh Hung Nguyen
    Department of Dengue Hemorrhagic Fever, Children s Hospital No 1 Ho Chi Minh City, Vietnam
    J Infect Dis 189:221-32. 2004
    ..Overproduction of both proinflammatory cytokines (interferon-gamma and tumor necrosis factor-alpha) and anti-inflammatory cytokines (interleukin-10 and -6) may play a role in the pathogenesis of DHF/DSS in infants...
  37. ncbi Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com
    J B Tandan
    Council for Technical Education and Vocational Training, P O Box 3546, Sanothimi, Bhaktapur, Kathmandu, Nepal
    Vaccine 25:5041-5. 2007
    ..1%) while only one of 20 JE cases had received live-attenuated JE vaccine. Five years after administration of a single dose, SA 14-14-2 provided a protective efficacy of 96.2% (CI 73.1-99.9%)...
  38. ncbi Recombination and flavivirus vaccines: a commentary
    Thomas P Monath
    Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
    Vaccine 23:2956-8. 2005